Ms. Dean (for herself, Mr. Veasey, Mr. Carter of Georgia, and Mr. McKinley) introduced the following bill; which was referred to the Committee on Energy and Commerce
To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs, and for other purposes.
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. Fairness in Orphan Drug Exclusivity Act. H.R. 4712. 116th
Cong., 1st
sess., Introduced in House October 17, 2019. https://www.govinfo.gov/app/details/BILLS-116hr4712ih.
APA
Congress, House of Representatives (2019, October 17). Fairness in Orphan Drug Exclusivity Act (H.R. 4712 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-116hr4712ih.
MLA
United States, Congress, House of Representatives. Fairness in Orphan Drug Exclusivity Act. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-116hr4712ih. 116th Congress, H.R. 4712, Introduced in House 17 Oct. 2019.
Bluebook
H.R.4712 - 116th Congress (2019-2020): Fairness in Orphan Drug Exclusivity Act, H.R.4712, 116th Cong. (2019), https://www.govinfo.gov/app/details/BILLS-116hr4712ih.
